VCYT News and Press, Veracyte Inc. From 08/07/23

2023-08-07 17:35:56 ET Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.14 (-7.7% Y/Y) and the consensus Revenue Estimate is $83.09M (+14.0% Y/Y). Over the last 1 year, ...

Clinical utility study findings based on analysis of the National Cancer Institute’s SEER database Veracyte, Inc . (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized...

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update...

2023-07-19 01:15:36 ET Summary ARK Invest's 13F portfolio value increased by approximately 4% from $14.55B to $15.10B in Q2 2023, with holdings increasing from 221 to 222. The firm established a new 0.69% stake in Palantir Technologies while increasing stakes in Coinbase Global, U...

2023-07-11 17:08:02 ET Gainers: Incyte  ( NASDAQ: INCY ) +4% . Veracyte ( VCYT ) +4% . Kronos ( KRON ) +3% . Applied Optoelectronics  ( AAOI ) +3% . GoodRx  ( GDRX ) +3% . Losers: Silk Road  ( SI...

Findings presented at ENDO 2023 also confirm analytical validity of company’s TERT promoter gene mutation testing for thyroid nodule patients Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest th...

- A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma molecular test and capabilities - Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new da...

2023-05-31 10:45:37 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – May 31, 2023 – USA News Group –  With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days ...

Veracyte, Inc . (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights int...

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoraci...